They include imatinib mesylate (or “Gleevec”/“Glivec”) for BCR-ABL inhibition in Chronic Myeloid Leukemia (CML) [9] and for KIT inhibition in gastrointestinal stromal tumors (GIST) [10], respectively. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.